EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal - sources

BRUSSELS, Oct 2 (Reuters) - EU antitrust regulators will widen a probe into Zimmer Holdings Inc's $13.4 billion bid for Biomet Inc but clear Eli Lilly's offer for a Novartis AG unit, three people familiar with the matter said on Thursday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.